Medicare’s Cancer Drug Payments Meet Most Oncologists’ Costs, OIG Says
An HHS Office of Inspector General report says most oncology practices receive adequate reimbursement from Medicare for the drugs they use, but the American Society of Clinical Oncology is disputing the relevance of the findings, saying they are based on outdated data
You may also be interested in...
CEOs of smaller biotech companies are often on the road trying to raise money or look at licensing deals. The ability to answer key reimbursement questions gives them a competitive advantage over their counterparts.
There is a new variable to consider in drug development: which Medicare coverage system is more desirable: the Part B system for physician-administered drugs or Part D for the traditional retail market. But why choose one when you can play in both?
The International Fragrance Association North America took a break from its higher-stakes advocacy work Nov. 1 to give lawmakers and congressional staffers a "scent experience." Perfumers from six of the group's biggest members were on hand with "Scents of Home," joined by Monell Center researchers to educate attendees on the mechanics of scent and the important role it plays in people's lives.